经鼻高流量湿化氧疗治疗慢阻肺急性加重合并Ⅱ型呼吸衰竭的临床效果OA

Objective:To evaluate the clinical efficacy of nasal high-flow humidified oxygen therapy as a ventilatory support for acute exacerbation of COPD complicated by type Ⅱ respiratory failure.Methods:A cohort of 81 patients presenting with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and concurrent type Ⅱ respiratory failure was en-rolled,all from Yizheng People's Hospital,were included from January 2023 to June 2025.Grouping based on differences in treatment regimens.The control group(n=40)was treated with non-invasive positive pressure ventilation;The obser-vation group(n=41)received a ventilation regimen of nasal high-flow humidified chemotherapy.Blood gas indicators and lung function were compared between the two groups to assess the risk of complications.Results:After treatment,blood gas indicators(oxygen partial pressure,blood oxygen saturation,carbon dioxide partial pressure)in the observation group were better than those in the control group(P<0.05).The peak expiratory flow,forced expiratory volume at the first sec-ond and forced vital capacity compared with the control group,the observation group showed markedly elevated levels(P<0.05).The complication rate compared with the control group,the observation group showed markedly elevated levels(P<0.05).Conclusion:Among patients presenting with acute exacerbation of COPD complicated by type Ⅱ respiratory failure,choosing high-flow intranasal humidified chemotherapy for ventilation can improve blood gas indicators and lung function,reducing the risk of complications.